50 results about "Cellular transplantation" patented technology

The present invention provides a method for treating an injury of a spinal cord of a patient. The method includes implanting a therapeutic substance in the spinal cord under indirect visualization. The indirect visualization may be provided by an endoscope, and the therapeutic substance may include cells. The present invention also provides a device for treating an injury of the spinal cord. The device includes skin visualization means for visualizing the spinal cord through a skin puncture, and injection means for injecting a therapeutic substance into the spinal cord.

The present invention relates to non-lethal methods of conditioning a recipient for bone marrow transplantation. In particular, it relates to the use of nonlethal doses of total body irradiation, total lymphoid irradiation, cell type-specific or cell marker-specific antibodies, especially antibodies directed to bone marrow stromal cell markers, NK cells, or the CD8 cell marker, cytotoxic drugs, or a combination thereof. The methods of the invention have a wide range of applications, including, but not limited to, the conditioning of an individual for hematopoietic reconstitution by bone marrow transplantation for the treatment of hematologic malignancies, hematologic disorders, autoimmunity, infectious diseases such as acquired immunodeficiency syndrome, and the engraftment of bone marrow cells to induce tolerance for solid organ, tissue and cellular transplantation.

The invention discloses a tissue engineering material-based culture method and applications of melanophore. In the method of the invention, the tissue engineering technology is used to build carrier material with good biocompatibility and perform culture (co-culture) and transfer of melanophore or melanophore, fibroblast and keratinocyte and the method can be used in depigmentation diseases such as vitiligo and for the regulation of skin color. The invention relates to the preparation of the carrier material with biocompatibility and the building and transplanting of the cell-carrier composite material. The carrier material can be used to provide good carrier for cell culture, maintain cellular activity and solve the problem that the cell suspension is easy to lose in the cellular transplantation process; the inoculum density and culture time of cells can be regulated at the same time, the regulation to the skin colors of different individuals can be realized; and the carrier materialhas good performances such as damage resistance, tear resistance and easy transfer, has good function of promoting wound healing, and satisfies the use requirements of the large-area depigmentation disease and the regulation of skin color.

The present invention is related to a composition for the treatment of articular cartilage damage or loss or defect. The composition for the treatment of articular cartilage injury of the present invention is characterized by that it is composed of cellular components separated, proliferated, and/or differentiated from the umbilical cord blood and their media, or of the above cellular components, their media, and biocompatible polymers. Compared to the conventional cells used for the treatment of articular cartilage damage, cellular components of the composition of the present invention have very superior ability of proliferation and differentiation and more easy to be collected and acquired. And the polymers of the composition of the present invention have one or more characteristics among the biocompatibility, biodegradation property and possible ability to serve to enhance nutrition of cells and possible ability to enhance formation of intercellular substrate as well as the mechanical strength and flexibility to the degree which is proper for cellular transplantation and generation of cartilage tissues.

The present invention provides a method that embryo of human embryonic stem cells (HES) is directionally induced and divided into liver cells. First, the biological property of high degree of self-regeneration multiplication of HES cell is made use of, the collagenase IV digestion is adopted for transfer of culture and augmentation, thereby obtaining a plurality of stem cells; second, the HES cell is inoculated into a cell utensil with lower adsorbability to form a mature imitated embryonic plant (EB); third, the mature cystic EB is digested with 0.25 tryptic enzyme to 0.02 percent EDTA to a single cell, and then is inoculated to a tissue culture dish which is packed with I-shaped collagen in advance, solution culture is induced under the condition of dexamethasone and human trypsin, and the differentiation towards the liver cell direction is observed and judged. The prevent invention provides the method that the HES is efficiently divided into liver cells, at the same time, the method makes the follow-up judging work more simply and more efficient, and lay a foundation for the stem cellular transplantation or biologic artificial liver curing the disease such as serious hepatitis, hepatic failure and so on.

The invention provides a pretreatment method for improving the migration capability of mesenchymal stem cells, and the method comprises the following steps: placing the mesenchymal stem cells with stable passage in a serum-free pretreatment culture medium, culturing for 4-5 days, and getting the mesenchymal stem cells after treatment for cellular transplantation, wherein the serum-free pretreatment culture medium comprises 1 multiplied by N2 additive, 1 multiplied by B27 additive, 5-20ng/ml of IGF (insulin-like growth factor), 5-20ng/ml of PDGF (platelet-derived growth factor) or bFGF (basic fibroblast growth factor), and a solvent is low glucose DMEM (Dulbecco minimum essential medium) culture medium or a high glucose DMEM culture medium. By culturing through the serum-free pretreatment culture medium, the cytological features of the MSC (mesenchymal stem cells) can be kept, the migration capability of the MSC after in vivo transplantation can be effectively improved and the capability of treating various injuries and diseases through the transplantation of the MSC can be further improved.

An electromagnetic field is applied to transplanted cells during their transplantation culturing to a chi eve confluence and alignment of transplanted cells into damaged tissue and organs, therefore improving the synchronization of electrical and mechanical tissue or organ functions. The electromagnetic field may be applied by catheter based to a selected portion of tissue or to the entire surface of a hollow body cavity or organ, such as heart chamber. The electromagnetic field is provided by an expansible net or array from a catheter or on an inflatable balloon or stent. The electromagnetic field is also provided by an implantable net or array of electrodes which may either be hardwired to a pulse generator or coupled by means of wireless or inductive transmission.

The invention relates to a medicine for curing osteonecrosis, belonging to the field of regenerative medicine engineering. Human amniotic mesenchymal cells (hAMCs) are used as cell source for cellular transplantation and tissue organization so as to cure the osteonecrosis and to provide a new way for repairing a damaged osseous tissue and reorganizing tissues. Based on the multi-lineage differentiation potential of the hAMCs, osteocytes, osseous tissues and vascular endotheliums can be differentiated in the human body, thereby completing the processes of osteanagenesis, bone remodeling and vascularization and forming a new osseous tissue integrated with the tissues of the patient.

The invention provides a Chinese sturgeon boule gene sequence and application thereof. A Chinese sturgeon boule gene has a cDNA (complementary Desoxvribose Nucleic Acid) sequence which is 2585bp in total length, has an open reading frame which is1065bp, codes 354 amino acids, and has a nucleotide sequence shown as SEQ ID No.1 and an amino acid sequence shown in SEQ ID No.2. The Chinese sturgeon boule gene sequence can be applied to identification, tracing and separation of germ cells of Chinese sturgeon, and lays a foundation for application and research on aspects of germ cellular transplantation, germplasm resource storage and the like of the Chinese sturgeon.

Embodiments of the invention relate generally to methods of diagnosing, classifying, and/or identifying a patient's risk of developing graft versus host disease, including severe or lethal graft versus host disease, after receiving hematopoietic cellular transplantation, a transfusion or a transplantation, but before the onset of clinical symptoms.

The invention discloses a method for promoting reprogramming of mouse fibroblasts into myocardial cells under low oxygen conditions. A reprogramming factor is utilized to directly reprogram mouse fibroblasts into efficiently differentiated myocardial cells; on such basis, the efficiency of low oxygen on direct reprogramming to generate myocardial cells and the variation of the HIF-1 expression level in the reprogramming process from fibroblasts to myocardial cells are detected, and the effect of low oxygen on the cell direct reprogramming is systematically explained. The expression conditions of the multi-potential transcription factor and epigenetic regulation factor under low oxygen stimulation are detected. The individualized myocardial cells obtained by directly reprogramming body cells are used for repairing myocardial infarction, thereby laying a foundation for enhancing the clinical cellular transplantation efficiency and safety. The research of the relationship between the low oxygen microenvironment and reprogramming provides a new idea for researching the reprogramming mechanism under low oxygen conditions.

The present disclosure is directed to systems, methods, and compositions for functional interaction of fibroblasts with one or more types of immune cells such that the interaction results in modification to the fibroblasts, the one or more types of immune cells, or both. In some embodiments, one or more certain agents are also utilized during the interaction or in lieu of one of the types of cells. In specific embodiments, cells to be used in cellular transplantation therapy are modified to have reduced immunogenicity.

The invention belongs to the technical field of tissue repair medicines, and particularly relates to application of a TGF-beta inhibitor in preparation of a medicine for treating diabetic foot. Aiming at the problems that cells are easy to apoptosis and the treatment effect of cell transplantation is not lasting when the cells are used for treating the diabetic foot, the invention provides the application of the TGF-beta inhibitor in preparing the medicine for treating the diabetic foot, and the TGF-beta inhibitor is proved to be capable of promoting the cells to maintain the mitochondrial membrane potential to be stable under the conditions of high glucose and low nutrition; and the intracellular active oxygen level is reduced, so that the cells maintain good proliferative activity and vascularization function. The function-enhanced endothelial cells obtained through induction and domestication culture of the TGF-beta inhibitor can survive for a long time in limbs of the ischemic diabetic foot of a mouse and form new vessels, and the treatment effect of endothelial cell transplantation on the ischemic diabetic foot is improved. According to the invention, the application range of the TGF-beta inhibitor is widened, a more effective method is provided for the cell therapy of diabetic foot, and the TGF-beta inhibitor has a good prospect.

A method of preparing a transplant site for cellular transplantation in a mammal includes the steps of inserting a foreign body comprising a biomaterial into an internal tissue; and removing the foreign body after the tissue surrounding the foreign body has undergone an inflammatory response but before significant fibrous encapsulation has occurred, leaving a neovascularized lumen suitable to receive transplanted cells or islets.

The present invention provides methods for enhancing cellular transplantation by exposing cells in vitro or ex vivo, or a recipient of cells, to a small molecule hepatocyte growth factor/scatter factor mimetic. Exemplary compounds are described.

The invention belongs to the field of biological medicine research, and particularly provides application of a transcription factor in one or more of the following items: preparing a medicine for treating retinal diseases; preparing a retina ganglion cell regeneration product; preparing a product for inducing adult cells to be reprogrammed into retinal ganglion cells; and preparing retinal ganglion cells. The transcription factor is selected from any one or more of Brn3B, Sox4, Atoh7, Sox11 and Isl1. A cell material used for regenerating the retinal ganglion cell is an endogenous cell of the retina ganglion cell, and compared with a cell transplantation mode, the retina ganglion cell has no immunological rejection and tumor formation risk; and the virus expression gene is simple, convenient and easy to popularize.